5[2]Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage Ⅲ non-small-cell lung cancer: sevenyear follow-up of cancer and leukemia group B (CALGB) 8433 trial[J]. J Natl Cancer Inst, 1996,88(17): 1210-1215.
6[3]Chu DT,Zhang XR,Li JL,et al. The treatment of advanced non-small-cell lung Cancer (NSCLC) overseas updated and local experiences[J]. Can To Kagaku ryoho, 2002,29 ( suppl 1):117-124.
7[4]Cardend F, Domine M, Massuti B, et al. Three-week schedule of irinotecan and cisplatin in advanced non-smallcell lung cancer: a multicenter phase Ⅱ study[J]. Lung Cancer, 2003,39(2): 201-207.
8[5]Zaniboni A, Ardizzoni A, De Marinis F, et al. Phase ⅡSyudy of Taxol combined with ifosfamide and carboplatin in the treatment of stage Ⅲ B-Ⅳ non-small-cell lung cancer[J]. Am J Clin Oncol, 2003,26(1): 84-88.
9[7]Montazeri A, Milroy R, Hole D, et al. Quality of life in lung cancer patients as a important prognostic factor[J]. Lung Cancer,2001,3(2-3) :223-240.
10[1]Heny wagner Jr. Radiation therapy in the management of patients with unresectable stage Ⅲ A and Ⅲ B non-small cell lung cancer [J].Seminars in Oncology, 1997, 24 (4): 423 - 428.
